INVESTER I RALLYBIO MED ENDAVU: Køb Rallybio ($33M0) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Rallybio, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Rallybio Corporation is a clinical-stage biotechnology company focused on developing and commercializing therapies for patients with severe and rare diseases. The company concentrates on areas of maternal-fetal health, complement dysregulation, hematology, and metabolic disorders, targeting conditions with significant unmet medical need. Its pipeline includes RLYB212, an anti-HPA-1a antibody being developed to prevent fetal and neonatal alloimmune thrombocytopenia, a rare disorder that can lead to dangerous bleeding in fetuses and newborns. Another key program is RLYB116, a differentiated inhibitor of complement component 5 (C5) intended for treatment of diseases driven by complement-mediated inflammation and tissue damage. Rallybio also advances preclinical assets such as RLYB332, a long-acting matriptase-2 antibody for diseases associated with iron overload. Operating today as a specialized player in the orphan drug and rare disease segment of the biopharmaceutical industry, Rallybio serves the healthcare and biotechnology markets from its headquarters in New Haven, Connecticut, where it was founded in 2018.